nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CYP2C19—prostate cancer	0.398	1	CbGaD
Methsuximide—CYP2C19—Nilutamide—prostate cancer	0.0937	0.288	CbGbCtD
Methsuximide—CYP2C19—Bicalutamide—prostate cancer	0.0937	0.288	CbGbCtD
Methsuximide—CYP2C19—Flutamide—prostate cancer	0.0777	0.239	CbGbCtD
Methsuximide—CYP2C19—Estradiol—prostate cancer	0.0323	0.0992	CbGbCtD
Methsuximide—CYP2C19—Prednisone—prostate cancer	0.0277	0.0853	CbGbCtD
Methsuximide—CYP2C19—urine—prostate cancer	0.00293	0.236	CbGeAlD
Methsuximide—CACNA1H—prostate gland—prostate cancer	0.00221	0.178	CbGeAlD
Methsuximide—CACNA1I—testis—prostate cancer	0.00217	0.175	CbGeAlD
Methsuximide—CACNA1H—seminal vesicle—prostate cancer	0.00187	0.15	CbGeAlD
Methsuximide—CACNA1I—lymph node—prostate cancer	0.00157	0.127	CbGeAlD
Methsuximide—CACNA1H—testis—prostate cancer	0.000973	0.0783	CbGeAlD
Methsuximide—Aminophenazone—CYP17A1—prostate cancer	0.000971	0.128	CrCbGaD
Methsuximide—Aminophenazone—CYP2C18—prostate cancer	0.000813	0.108	CrCbGaD
Methsuximide—CACNA1H—lymph node—prostate cancer	0.000705	0.0568	CbGeAlD
Methsuximide—Antipyrine—CYP2C18—prostate cancer	0.000512	0.0677	CrCbGaD
Methsuximide—Headache—Degarelix—prostate cancer	0.000427	0.0027	CcSEcCtD
Methsuximide—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000426	0.00269	CcSEcCtD
Methsuximide—Dizziness—Cabazitaxel—prostate cancer	0.000425	0.00268	CcSEcCtD
Methsuximide—Haematuria—Mitoxantrone—prostate cancer	0.000424	0.00267	CcSEcCtD
Methsuximide—Leukopenia—Goserelin—prostate cancer	0.000421	0.00266	CcSEcCtD
Methsuximide—Vomiting—Cabazitaxel—prostate cancer	0.000409	0.00258	CcSEcCtD
Methsuximide—Nausea—Degarelix—prostate cancer	0.000405	0.00256	CcSEcCtD
Methsuximide—Erythema multiforme—Estradiol—prostate cancer	0.000405	0.00256	CcSEcCtD
Methsuximide—Headache—Cabazitaxel—prostate cancer	0.000403	0.00254	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000402	0.00254	CcSEcCtD
Methsuximide—Constipation—Ethinyl Estradiol—prostate cancer	0.000399	0.00252	CcSEcCtD
Methsuximide—Pancytopenia—Etoposide—prostate cancer	0.000394	0.00248	CcSEcCtD
Methsuximide—Confusional state—Goserelin—prostate cancer	0.000387	0.00244	CcSEcCtD
Methsuximide—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.000384	0.00242	CcSEcCtD
Methsuximide—Nausea—Cabazitaxel—prostate cancer	0.000382	0.00241	CcSEcCtD
Methsuximide—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.000381	0.00241	CcSEcCtD
Methsuximide—Diarrhoea—Bicalutamide—prostate cancer	0.000377	0.00238	CcSEcCtD
Methsuximide—Ataxia—Docetaxel—prostate cancer	0.000375	0.00237	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—prostate cancer	0.00037	0.00234	CcSEcCtD
Methsuximide—Urticaria—Ethinyl Estradiol—prostate cancer	0.00037	0.00234	CcSEcCtD
Methsuximide—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000368	0.00233	CcSEcCtD
Methsuximide—Irritability—Capecitabine—prostate cancer	0.000368	0.00233	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Etoposide—prostate cancer	0.000366	0.00231	CcSEcCtD
Methsuximide—Anorexia—Goserelin—prostate cancer	0.000366	0.00231	CcSEcCtD
Methsuximide—Tension—Estradiol—prostate cancer	0.000366	0.00231	CcSEcCtD
Methsuximide—Aminophenazone—CYP2C19—prostate cancer	0.000365	0.0482	CrCbGaD
Methsuximide—Dizziness—Bicalutamide—prostate cancer	0.000365	0.0023	CcSEcCtD
Methsuximide—Ataxia—Capecitabine—prostate cancer	0.000363	0.00229	CcSEcCtD
Methsuximide—Anorexia—Conjugated Estrogens—prostate cancer	0.000362	0.00229	CcSEcCtD
Methsuximide—Nervousness—Estradiol—prostate cancer	0.000362	0.00228	CcSEcCtD
Methsuximide—Vomiting—Bicalutamide—prostate cancer	0.000351	0.00221	CcSEcCtD
Methsuximide—Rash—Bicalutamide—prostate cancer	0.000348	0.0022	CcSEcCtD
Methsuximide—Dermatitis—Bicalutamide—prostate cancer	0.000347	0.00219	CcSEcCtD
Methsuximide—Insomnia—Goserelin—prostate cancer	0.000347	0.00219	CcSEcCtD
Methsuximide—Headache—Bicalutamide—prostate cancer	0.000345	0.00218	CcSEcCtD
Methsuximide—Insomnia—Conjugated Estrogens—prostate cancer	0.000344	0.00217	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—prostate cancer	0.000343	0.00216	CcSEcCtD
Methsuximide—Somnolence—Goserelin—prostate cancer	0.000341	0.00215	CcSEcCtD
Methsuximide—Somnolence—Conjugated Estrogens—prostate cancer	0.000338	0.00213	CcSEcCtD
Methsuximide—Psychotic disorder—Prednisone—prostate cancer	0.000336	0.00212	CcSEcCtD
Methsuximide—Decreased appetite—Goserelin—prostate cancer	0.000333	0.00211	CcSEcCtD
Methsuximide—Decreased appetite—Conjugated Estrogens—prostate cancer	0.00033	0.00209	CcSEcCtD
Methsuximide—Irritability—Prednisone—prostate cancer	0.000328	0.00207	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000328	0.00207	CcSEcCtD
Methsuximide—Constipation—Goserelin—prostate cancer	0.000328	0.00207	CcSEcCtD
Methsuximide—Nausea—Bicalutamide—prostate cancer	0.000328	0.00207	CcSEcCtD
Methsuximide—Vision blurred—Mitoxantrone—prostate cancer	0.000327	0.00207	CcSEcCtD
Methsuximide—Pancytopenia—Docetaxel—prostate cancer	0.000327	0.00207	CcSEcCtD
Methsuximide—Antipyrine—CYP2A6—prostate cancer	0.000326	0.0432	CrCbGaD
Methsuximide—Constipation—Conjugated Estrogens—prostate cancer	0.000325	0.00205	CcSEcCtD
Methsuximide—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000319	0.00201	CcSEcCtD
Methsuximide—Pancytopenia—Capecitabine—prostate cancer	0.000317	0.002	CcSEcCtD
Methsuximide—Feeling abnormal—Goserelin—prostate cancer	0.000316	0.002	CcSEcCtD
Methsuximide—Gastrointestinal pain—Goserelin—prostate cancer	0.000314	0.00198	CcSEcCtD
Methsuximide—Erythema multiforme—Etoposide—prostate cancer	0.000314	0.00198	CcSEcCtD
Methsuximide—Weight decreased—Docetaxel—prostate cancer	0.000312	0.00197	CcSEcCtD
Methsuximide—Leukopenia—Mitoxantrone—prostate cancer	0.000311	0.00196	CcSEcCtD
Methsuximide—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000311	0.00196	CcSEcCtD
Methsuximide—Dizziness—Ethinyl Estradiol—prostate cancer	0.000308	0.00195	CcSEcCtD
Methsuximide—Confusional state—Estradiol—prostate cancer	0.000307	0.00194	CcSEcCtD
Methsuximide—Urticaria—Goserelin—prostate cancer	0.000305	0.00192	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000304	0.00192	CcSEcCtD
Methsuximide—Abdominal pain—Goserelin—prostate cancer	0.000303	0.00191	CcSEcCtD
Methsuximide—Urticaria—Conjugated Estrogens—prostate cancer	0.000302	0.00191	CcSEcCtD
Methsuximide—Weight decreased—Capecitabine—prostate cancer	0.000302	0.0019	CcSEcCtD
Methsuximide—Abdominal pain—Conjugated Estrogens—prostate cancer	0.0003	0.0019	CcSEcCtD
Methsuximide—Vomiting—Ethinyl Estradiol—prostate cancer	0.000296	0.00187	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000295	0.00186	CcSEcCtD
Methsuximide—Rash—Ethinyl Estradiol—prostate cancer	0.000294	0.00186	CcSEcCtD
Methsuximide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000294	0.00185	CcSEcCtD
Methsuximide—Headache—Ethinyl Estradiol—prostate cancer	0.000292	0.00184	CcSEcCtD
Methsuximide—Clobazam—CYP2C18—prostate cancer	0.000286	0.0378	CrCbGaD
Methsuximide—Confusional state—Mitoxantrone—prostate cancer	0.000286	0.0018	CcSEcCtD
Methsuximide—Haematuria—Capecitabine—prostate cancer	0.000284	0.00179	CcSEcCtD
Methsuximide—Nausea—Ethinyl Estradiol—prostate cancer	0.000277	0.00175	CcSEcCtD
Methsuximide—Insomnia—Estradiol—prostate cancer	0.000275	0.00174	CcSEcCtD
Methsuximide—Somnolence—Estradiol—prostate cancer	0.00027	0.00171	CcSEcCtD
Methsuximide—Anorexia—Mitoxantrone—prostate cancer	0.00027	0.00171	CcSEcCtD
Methsuximide—Weight decreased—Prednisone—prostate cancer	0.000269	0.0017	CcSEcCtD
Methsuximide—Decreased appetite—Estradiol—prostate cancer	0.000264	0.00167	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Estradiol—prostate cancer	0.000263	0.00166	CcSEcCtD
Methsuximide—Diarrhoea—Goserelin—prostate cancer	0.000262	0.00166	CcSEcCtD
Methsuximide—Phenytoin—CYP2C18—prostate cancer	0.000261	0.0345	CrCbGaD
Methsuximide—Erythema multiforme—Docetaxel—prostate cancer	0.000261	0.00165	CcSEcCtD
Methsuximide—Constipation—Estradiol—prostate cancer	0.00026	0.00164	CcSEcCtD
Methsuximide—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00026	0.00164	CcSEcCtD
Methsuximide—Phensuximide—CYP2C19—prostate cancer	0.000259	0.0342	CrCbGaD
Methsuximide—Leukopenia—Etoposide—prostate cancer	0.000259	0.00163	CcSEcCtD
Methsuximide—Dizziness—Goserelin—prostate cancer	0.000254	0.0016	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—prostate cancer	0.000253	0.0016	CcSEcCtD
Methsuximide—Erythema multiforme—Capecitabine—prostate cancer	0.000252	0.00159	CcSEcCtD
Methsuximide—Somnolence—Mitoxantrone—prostate cancer	0.000252	0.00159	CcSEcCtD
Methsuximide—Dizziness—Conjugated Estrogens—prostate cancer	0.000251	0.00159	CcSEcCtD
Methsuximide—Feeling abnormal—Estradiol—prostate cancer	0.000251	0.00158	CcSEcCtD
Methsuximide—Phenobarbital—CYP2C18—prostate cancer	0.00025	0.0331	CrCbGaD
Methsuximide—Gastrointestinal pain—Estradiol—prostate cancer	0.000249	0.00157	CcSEcCtD
Methsuximide—Decreased appetite—Mitoxantrone—prostate cancer	0.000246	0.00156	CcSEcCtD
Methsuximide—Vomiting—Goserelin—prostate cancer	0.000244	0.00154	CcSEcCtD
Methsuximide—Constipation—Mitoxantrone—prostate cancer	0.000242	0.00153	CcSEcCtD
Methsuximide—Rash—Goserelin—prostate cancer	0.000242	0.00153	CcSEcCtD
Methsuximide—Dermatitis—Goserelin—prostate cancer	0.000242	0.00153	CcSEcCtD
Methsuximide—Vomiting—Conjugated Estrogens—prostate cancer	0.000242	0.00153	CcSEcCtD
Methsuximide—Urticaria—Estradiol—prostate cancer	0.000242	0.00153	CcSEcCtD
Methsuximide—Abdominal pain—Estradiol—prostate cancer	0.00024	0.00152	CcSEcCtD
Methsuximide—Headache—Goserelin—prostate cancer	0.00024	0.00152	CcSEcCtD
Methsuximide—Rash—Conjugated Estrogens—prostate cancer	0.00024	0.00151	CcSEcCtD
Methsuximide—Dermatitis—Conjugated Estrogens—prostate cancer	0.000239	0.00151	CcSEcCtD
Methsuximide—Headache—Conjugated Estrogens—prostate cancer	0.000238	0.0015	CcSEcCtD
Methsuximide—Confusional state—Etoposide—prostate cancer	0.000238	0.0015	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—prostate cancer	0.000234	0.00148	CcSEcCtD
Methsuximide—Feeling abnormal—Mitoxantrone—prostate cancer	0.000234	0.00147	CcSEcCtD
Methsuximide—Aminophenazone—CYP3A4—prostate cancer	0.000232	0.0307	CrCbGaD
Methsuximide—Antipyrine—CYP2E1—prostate cancer	0.000232	0.0307	CrCbGaD
Methsuximide—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000232	0.00146	CcSEcCtD
Methsuximide—Eosinophilia—Epirubicin—prostate cancer	0.00023	0.00145	CcSEcCtD
Methsuximide—Antipyrine—CYP2C19—prostate cancer	0.00023	0.0304	CrCbGaD
Methsuximide—Nausea—Goserelin—prostate cancer	0.000228	0.00144	CcSEcCtD
Methsuximide—Nausea—Conjugated Estrogens—prostate cancer	0.000226	0.00142	CcSEcCtD
Methsuximide—Urticaria—Mitoxantrone—prostate cancer	0.000225	0.00142	CcSEcCtD
Methsuximide—Anorexia—Etoposide—prostate cancer	0.000225	0.00142	CcSEcCtD
Methsuximide—Abdominal pain—Mitoxantrone—prostate cancer	0.000224	0.00141	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—prostate cancer	0.000221	0.00139	CcSEcCtD
Methsuximide—Vision blurred—Capecitabine—prostate cancer	0.000219	0.00138	CcSEcCtD
Methsuximide—Leukopenia—Docetaxel—prostate cancer	0.000215	0.00136	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—prostate cancer	0.000213	0.00134	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—prostate cancer	0.00021	0.00133	CcSEcCtD
Methsuximide—Somnolence—Etoposide—prostate cancer	0.00021	0.00132	CcSEcCtD
Methsuximide—Diarrhoea—Estradiol—prostate cancer	0.000208	0.00131	CcSEcCtD
Methsuximide—Leukopenia—Capecitabine—prostate cancer	0.000208	0.00131	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—prostate cancer	0.000207	0.00131	CcSEcCtD
Methsuximide—Phenobarbital—CYP1B1—prostate cancer	0.000207	0.0274	CrCbGaD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000205	0.0013	CcSEcCtD
Methsuximide—Decreased appetite—Etoposide—prostate cancer	0.000205	0.00129	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—prostate cancer	0.000204	0.00129	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—prostate cancer	0.000203	0.00128	CcSEcCtD
Methsuximide—Constipation—Etoposide—prostate cancer	0.000202	0.00127	CcSEcCtD
Methsuximide—Dizziness—Estradiol—prostate cancer	0.000201	0.00127	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—prostate cancer	0.000198	0.00125	CcSEcCtD
Methsuximide—Confusional state—Docetaxel—prostate cancer	0.000198	0.00125	CcSEcCtD
Methsuximide—Vision blurred—Prednisone—prostate cancer	0.000195	0.00123	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—prostate cancer	0.000194	0.00123	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—prostate cancer	0.000194	0.00123	CcSEcCtD
Methsuximide—Diarrhoea—Mitoxantrone—prostate cancer	0.000194	0.00122	CcSEcCtD
Methsuximide—Vomiting—Estradiol—prostate cancer	0.000193	0.00122	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—prostate cancer	0.000193	0.00122	CcSEcCtD
Methsuximide—Rash—Estradiol—prostate cancer	0.000192	0.00121	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—prostate cancer	0.000192	0.00121	CcSEcCtD
Methsuximide—Ethotoin—CYP2C19—prostate cancer	0.000192	0.0253	CrCbGaD
Methsuximide—Dermatitis—Estradiol—prostate cancer	0.000192	0.00121	CcSEcCtD
Methsuximide—Confusional state—Capecitabine—prostate cancer	0.000191	0.00121	CcSEcCtD
Methsuximide—Headache—Estradiol—prostate cancer	0.000191	0.0012	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.00019	0.0012	CcSEcCtD
Methsuximide—Urticaria—Etoposide—prostate cancer	0.000187	0.00118	CcSEcCtD
Methsuximide—Anorexia—Docetaxel—prostate cancer	0.000187	0.00118	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—prostate cancer	0.000186	0.00118	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—prostate cancer	0.000183	0.00115	CcSEcCtD
Methsuximide—Anorexia—Capecitabine—prostate cancer	0.000181	0.00114	CcSEcCtD
Methsuximide—Nausea—Estradiol—prostate cancer	0.000181	0.00114	CcSEcCtD
Methsuximide—Vomiting—Mitoxantrone—prostate cancer	0.00018	0.00114	CcSEcCtD
Methsuximide—Rash—Mitoxantrone—prostate cancer	0.000179	0.00113	CcSEcCtD
Methsuximide—Dermatitis—Mitoxantrone—prostate cancer	0.000178	0.00113	CcSEcCtD
Methsuximide—Primidone—CYP2C19—prostate cancer	0.000178	0.0235	CrCbGaD
Methsuximide—Headache—Mitoxantrone—prostate cancer	0.000178	0.00112	CcSEcCtD
Methsuximide—Insomnia—Docetaxel—prostate cancer	0.000177	0.00112	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—prostate cancer	0.000176	0.00111	CcSEcCtD
Methsuximide—Somnolence—Docetaxel—prostate cancer	0.000174	0.0011	CcSEcCtD
Methsuximide—Phenytoin—CYP3A5—prostate cancer	0.000172	0.0227	CrCbGaD
Methsuximide—Insomnia—Capecitabine—prostate cancer	0.000172	0.00108	CcSEcCtD
Methsuximide—Decreased appetite—Docetaxel—prostate cancer	0.00017	0.00107	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000169	0.00107	CcSEcCtD
Methsuximide—Nausea—Mitoxantrone—prostate cancer	0.000168	0.00106	CcSEcCtD
Methsuximide—Constipation—Docetaxel—prostate cancer	0.000168	0.00106	CcSEcCtD
Methsuximide—Methylphenobarbital—CYP2C19—prostate cancer	0.000167	0.022	CrCbGaD
Methsuximide—Decreased appetite—Capecitabine—prostate cancer	0.000165	0.00104	CcSEcCtD
Methsuximide—Phenobarbital—CYP3A5—prostate cancer	0.000165	0.0218	CrCbGaD
Methsuximide—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000164	0.00103	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—prostate cancer	0.000163	0.00103	CcSEcCtD
Methsuximide—Constipation—Capecitabine—prostate cancer	0.000162	0.00102	CcSEcCtD
Methsuximide—Feeling abnormal—Docetaxel—prostate cancer	0.000161	0.00102	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—prostate cancer	0.000161	0.00102	CcSEcCtD
Methsuximide—Anorexia—Prednisone—prostate cancer	0.000161	0.00102	CcSEcCtD
Methsuximide—Gastrointestinal pain—Docetaxel—prostate cancer	0.00016	0.00101	CcSEcCtD
Methsuximide—Phenobarbital—CYP2A6—prostate cancer	0.000159	0.0211	CrCbGaD
Methsuximide—Tension—Epirubicin—prostate cancer	0.000159	0.001	CcSEcCtD
Methsuximide—Pethidine—CYP2C19—prostate cancer	0.000159	0.021	CrCbGaD
Methsuximide—Nervousness—Epirubicin—prostate cancer	0.000157	0.000993	CcSEcCtD
Methsuximide—Feeling abnormal—Capecitabine—prostate cancer	0.000156	0.000987	CcSEcCtD
Methsuximide—Dizziness—Etoposide—prostate cancer	0.000156	0.000984	CcSEcCtD
Methsuximide—Gastrointestinal pain—Capecitabine—prostate cancer	0.000155	0.000979	CcSEcCtD
Methsuximide—Abdominal pain—Docetaxel—prostate cancer	0.000155	0.000978	CcSEcCtD
Methsuximide—Insomnia—Prednisone—prostate cancer	0.000153	0.000965	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—prostate cancer	0.000153	0.000963	CcSEcCtD
Methsuximide—Urticaria—Capecitabine—prostate cancer	0.000151	0.000951	CcSEcCtD
Methsuximide—Abdominal pain—Capecitabine—prostate cancer	0.00015	0.000946	CcSEcCtD
Methsuximide—Vomiting—Etoposide—prostate cancer	0.00015	0.000946	CcSEcCtD
Methsuximide—Rash—Etoposide—prostate cancer	0.000149	0.000938	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—prostate cancer	0.000148	0.000937	CcSEcCtD
Methsuximide—Headache—Etoposide—prostate cancer	0.000148	0.000932	CcSEcCtD
Methsuximide—Tension—Doxorubicin—prostate cancer	0.000147	0.000928	CcSEcCtD
Methsuximide—Decreased appetite—Prednisone—prostate cancer	0.000147	0.000927	CcSEcCtD
Methsuximide—Antipyrine—CYP3A4—prostate cancer	0.000146	0.0193	CrCbGaD
Methsuximide—Nervousness—Doxorubicin—prostate cancer	0.000145	0.000918	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—prostate cancer	0.000145	0.000915	CcSEcCtD
Methsuximide—Constipation—Prednisone—prostate cancer	0.000144	0.000912	CcSEcCtD
Methsuximide—Antipyrine—PTGS2—prostate cancer	0.000143	0.0189	CrCbGaD
Methsuximide—Vision blurred—Doxorubicin—prostate cancer	0.000141	0.000891	CcSEcCtD
Methsuximide—Nausea—Etoposide—prostate cancer	0.00014	0.000884	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisone—prostate cancer	0.000139	0.000879	CcSEcCtD
Methsuximide—Gastrointestinal pain—Prednisone—prostate cancer	0.000138	0.000872	CcSEcCtD
Methsuximide—Urticaria—Prednisone—prostate cancer	0.000134	0.000847	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—prostate cancer	0.000134	0.000846	CcSEcCtD
Methsuximide—Diarrhoea—Docetaxel—prostate cancer	0.000134	0.000846	CcSEcCtD
Methsuximide—Abdominal pain—Prednisone—prostate cancer	0.000134	0.000843	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—prostate cancer	0.000133	0.000841	CcSEcCtD
Methsuximide—Diarrhoea—Capecitabine—prostate cancer	0.00013	0.000819	CcSEcCtD
Methsuximide—Dizziness—Docetaxel—prostate cancer	0.00013	0.000818	CcSEcCtD
Methsuximide—Clobazam—CYP2C19—prostate cancer	0.000128	0.017	CrCbGaD
Methsuximide—Anorexia—Epirubicin—prostate cancer	0.000126	0.000795	CcSEcCtD
Methsuximide—Dizziness—Capecitabine—prostate cancer	0.000125	0.000792	CcSEcCtD
Methsuximide—Vomiting—Docetaxel—prostate cancer	0.000125	0.000786	CcSEcCtD
Methsuximide—Rash—Docetaxel—prostate cancer	0.000124	0.00078	CcSEcCtD
Methsuximide—Dermatitis—Docetaxel—prostate cancer	0.000123	0.000779	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—prostate cancer	0.000123	0.000778	CcSEcCtD
Methsuximide—Headache—Docetaxel—prostate cancer	0.000123	0.000775	CcSEcCtD
Methsuximide—Vomiting—Capecitabine—prostate cancer	0.000121	0.000761	CcSEcCtD
Methsuximide—Rash—Capecitabine—prostate cancer	0.00012	0.000755	CcSEcCtD
Methsuximide—Insomnia—Epirubicin—prostate cancer	0.000119	0.000754	CcSEcCtD
Methsuximide—Dermatitis—Capecitabine—prostate cancer	0.000119	0.000754	CcSEcCtD
Methsuximide—Headache—Capecitabine—prostate cancer	0.000119	0.00075	CcSEcCtD
Methsuximide—Somnolence—Epirubicin—prostate cancer	0.000117	0.000741	CcSEcCtD
Methsuximide—Phenytoin—CYP2C19—prostate cancer	0.000117	0.0155	CrCbGaD
Methsuximide—Anorexia—Doxorubicin—prostate cancer	0.000117	0.000736	CcSEcCtD
Methsuximide—Nausea—Docetaxel—prostate cancer	0.000116	0.000735	CcSEcCtD
Methsuximide—Diarrhoea—Prednisone—prostate cancer	0.000116	0.00073	CcSEcCtD
Methsuximide—Ketazolam—CYP3A4—prostate cancer	0.000115	0.0153	CrCbGaD
Methsuximide—Decreased appetite—Epirubicin—prostate cancer	0.000115	0.000725	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000114	0.00072	CcSEcCtD
Methsuximide—Phenobarbital—CYP2E1—prostate cancer	0.000113	0.015	CrCbGaD
Methsuximide—Constipation—Epirubicin—prostate cancer	0.000113	0.000713	CcSEcCtD
Methsuximide—Primidone—CYP3A4—prostate cancer	0.000113	0.0149	CrCbGaD
Methsuximide—Nausea—Capecitabine—prostate cancer	0.000113	0.000711	CcSEcCtD
Methsuximide—Phenobarbital—CYP2C19—prostate cancer	0.000112	0.0148	CrCbGaD
Methsuximide—Dizziness—Prednisone—prostate cancer	0.000112	0.000705	CcSEcCtD
Methsuximide—Phenobarbital—CYP1A1—prostate cancer	0.000112	0.0148	CrCbGaD
Methsuximide—Insomnia—Doxorubicin—prostate cancer	0.000111	0.000698	CcSEcCtD
Methsuximide—Feeling abnormal—Epirubicin—prostate cancer	0.000109	0.000687	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—prostate cancer	0.000109	0.000686	CcSEcCtD
Methsuximide—Gastrointestinal pain—Epirubicin—prostate cancer	0.000108	0.000682	CcSEcCtD
Methsuximide—Vomiting—Prednisone—prostate cancer	0.000107	0.000678	CcSEcCtD
Methsuximide—Rash—Prednisone—prostate cancer	0.000107	0.000672	CcSEcCtD
Methsuximide—Dermatitis—Prednisone—prostate cancer	0.000106	0.000672	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—prostate cancer	0.000106	0.000671	CcSEcCtD
Methsuximide—Headache—Prednisone—prostate cancer	0.000106	0.000668	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000106	0.000666	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—prostate cancer	0.000105	0.000663	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—prostate cancer	0.000105	0.00066	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—prostate cancer	0.000104	0.000659	CcSEcCtD
Methsuximide—Pethidine—CYP3A4—prostate cancer	0.000101	0.0134	CrCbGaD
Methsuximide—Feeling abnormal—Doxorubicin—prostate cancer	0.000101	0.000636	CcSEcCtD
Methsuximide—Nausea—Prednisone—prostate cancer	0.0001	0.000633	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—prostate cancer	0.0001	0.000631	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—prostate cancer	9.71e-05	0.000613	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—prostate cancer	9.66e-05	0.00061	CcSEcCtD
Methsuximide—Diarrhoea—Epirubicin—prostate cancer	9.04e-05	0.000571	CcSEcCtD
Methsuximide—Dizziness—Epirubicin—prostate cancer	8.74e-05	0.000552	CcSEcCtD
Methsuximide—Vomiting—Epirubicin—prostate cancer	8.4e-05	0.00053	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—prostate cancer	8.36e-05	0.000528	CcSEcCtD
Methsuximide—Rash—Epirubicin—prostate cancer	8.33e-05	0.000526	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—prostate cancer	8.32e-05	0.000525	CcSEcCtD
Methsuximide—Headache—Epirubicin—prostate cancer	8.28e-05	0.000523	CcSEcCtD
Methsuximide—Clobazam—CYP3A4—prostate cancer	8.16e-05	0.0108	CrCbGaD
Methsuximide—Dizziness—Doxorubicin—prostate cancer	8.08e-05	0.00051	CcSEcCtD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	7.92e-05	0.000808	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—SULT2A1—prostate cancer	7.9e-05	0.000806	CbGpPWpGaD
Methsuximide—Nausea—Epirubicin—prostate cancer	7.85e-05	0.000495	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—LEP—prostate cancer	7.83e-05	0.000798	CbGpPWpGaD
Methsuximide—Vomiting—Doxorubicin—prostate cancer	7.77e-05	0.000491	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—JAK2—prostate cancer	7.74e-05	0.000789	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—JAK2—prostate cancer	7.73e-05	0.000788	CbGpPWpGaD
Methsuximide—Rash—Doxorubicin—prostate cancer	7.71e-05	0.000487	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—prostate cancer	7.7e-05	0.000486	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—ERBB2—prostate cancer	7.69e-05	0.000784	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KDR—prostate cancer	7.67e-05	0.000782	CbGpPWpGaD
Methsuximide—Headache—Doxorubicin—prostate cancer	7.66e-05	0.000483	CcSEcCtD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—GRHL1—prostate cancer	7.6e-05	0.000775	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CBR1—prostate cancer	7.6e-05	0.000775	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—LEP—prostate cancer	7.58e-05	0.000773	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GPX3—prostate cancer	7.54e-05	0.000769	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ERBB2—prostate cancer	7.44e-05	0.000759	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—prostate cancer	7.44e-05	0.000759	CbGpPWpGaD
Methsuximide—Phenytoin—CYP3A4—prostate cancer	7.44e-05	0.00984	CrCbGaD
Methsuximide—CACNA1H—Developmental Biology—KDR—prostate cancer	7.43e-05	0.000757	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—prostate cancer	7.26e-05	0.000458	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—EGFR—prostate cancer	7.23e-05	0.000737	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—HPGDS—prostate cancer	7.19e-05	0.000733	CbGpPWpGaD
Methsuximide—Phenobarbital—CYP3A4—prostate cancer	7.13e-05	0.00943	CrCbGaD
Methsuximide—CYP2C19—Biological oxidations—GSTT1—prostate cancer	6.97e-05	0.000711	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP2A6—prostate cancer	6.89e-05	0.000702	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KRAS—prostate cancer	6.83e-05	0.000696	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—GSK3B—prostate cancer	6.78e-05	0.000691	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS2—prostate cancer	6.72e-05	0.000686	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—INS—prostate cancer	6.69e-05	0.000682	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—MBTPS1—prostate cancer	6.64e-05	0.000678	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—AKR1C3—prostate cancer	6.61e-05	0.000674	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP17A1—prostate cancer	6.6e-05	0.000673	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP9—prostate cancer	6.59e-05	0.000672	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—GSK3B—prostate cancer	6.57e-05	0.000669	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CREBBP—prostate cancer	6.55e-05	0.000668	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNB1—prostate cancer	6.51e-05	0.000664	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP17A1—prostate cancer	6.51e-05	0.000663	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—INS—prostate cancer	6.48e-05	0.00066	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—prostate cancer	6.39e-05	0.000651	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—prostate cancer	6.38e-05	0.000651	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CREBBP—prostate cancer	6.34e-05	0.000647	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—AMACR—prostate cancer	6.3e-05	0.000642	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—DEGS1—prostate cancer	6.3e-05	0.000642	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—prostate cancer	6.3e-05	0.000642	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—NCOA2—prostate cancer	6.29e-05	0.000641	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP2—prostate cancer	6.26e-05	0.000638	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAP2K1—prostate cancer	6.25e-05	0.000637	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—SRC—prostate cancer	6.08e-05	0.00062	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP2—prostate cancer	6.06e-05	0.000618	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAP2K1—prostate cancer	6.05e-05	0.000617	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EP300—prostate cancer	6.05e-05	0.000617	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B1—prostate cancer	6.01e-05	0.000613	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—FGF2—prostate cancer	5.95e-05	0.000606	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—prostate cancer	5.92e-05	0.000604	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—SRC—prostate cancer	5.89e-05	0.0006	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SRC—prostate cancer	5.88e-05	0.0006	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP2E1—prostate cancer	5.86e-05	0.000597	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP2E1—prostate cancer	5.78e-05	0.000589	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—FGF2—prostate cancer	5.76e-05	0.000587	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—prostate cancer	5.73e-05	0.000585	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—prostate cancer	5.73e-05	0.000584	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—JAK2—prostate cancer	5.7e-05	0.000581	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—STAT3—prostate cancer	5.67e-05	0.000579	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP3A4—prostate cancer	5.65e-05	0.000576	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP3A4—prostate cancer	5.57e-05	0.000568	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—IL6—prostate cancer	5.55e-05	0.000566	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1B1—prostate cancer	5.55e-05	0.000566	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—JAK2—prostate cancer	5.52e-05	0.000563	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—prostate cancer	5.49e-05	0.000559	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1B1—prostate cancer	5.48e-05	0.000558	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GGT1—prostate cancer	5.38e-05	0.000548	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—prostate cancer	5.36e-05	0.000546	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EGFR—prostate cancer	5.33e-05	0.000543	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—prostate cancer	5.31e-05	0.000542	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—NCOA1—prostate cancer	5.3e-05	0.00054	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TGFB1—prostate cancer	5.26e-05	0.000536	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP19A1—prostate cancer	5.22e-05	0.000532	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—prostate cancer	5.16e-05	0.000526	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—prostate cancer	5.16e-05	0.000526	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP19A1—prostate cancer	5.15e-05	0.000525	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—RXRA—prostate cancer	5.04e-05	0.000514	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	5.04e-05	0.000514	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—prostate cancer	5.03e-05	0.000513	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	4.9e-05	0.0005	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—prostate cancer	4.87e-05	0.000497	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—prostate cancer	4.87e-05	0.000497	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—COMT—prostate cancer	4.85e-05	0.000495	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTP1—prostate cancer	4.83e-05	0.000493	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNB1—prostate cancer	4.8e-05	0.000489	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—COMT—prostate cancer	4.79e-05	0.000488	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	4.77e-05	0.000487	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTP1—prostate cancer	4.76e-05	0.000486	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—prostate cancer	4.7e-05	0.00048	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNB1—prostate cancer	4.65e-05	0.000474	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—prostate cancer	4.56e-05	0.000465	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	4.55e-05	0.000464	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	4.55e-05	0.000464	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EP300—prostate cancer	4.46e-05	0.000455	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM1—prostate cancer	4.44e-05	0.000453	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM1—prostate cancer	4.38e-05	0.000446	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SRC—prostate cancer	4.34e-05	0.000442	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EP300—prostate cancer	4.32e-05	0.000441	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—prostate cancer	4.22e-05	0.000431	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1A1—prostate cancer	4.21e-05	0.000429	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SRC—prostate cancer	4.2e-05	0.000428	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—STAT3—prostate cancer	4.18e-05	0.000427	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HAO1—prostate cancer	4.15e-05	0.000423	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1A1—prostate cancer	4.15e-05	0.000423	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6—prostate cancer	4.09e-05	0.000418	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—prostate cancer	4.09e-05	0.000417	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—STAT3—prostate cancer	4.05e-05	0.000413	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6—prostate cancer	3.97e-05	0.000404	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6—prostate cancer	3.96e-05	0.000404	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TGFB1—prostate cancer	3.88e-05	0.000395	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	3.87e-05	0.000395	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—prostate cancer	3.8e-05	0.000388	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TGFB1—prostate cancer	3.76e-05	0.000383	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	3.71e-05	0.000379	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—prostate cancer	3.68e-05	0.000375	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—prostate cancer	3.66e-05	0.000373	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—prostate cancer	3.59e-05	0.000366	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	3.57e-05	0.000364	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—prostate cancer	3.48e-05	0.000355	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	3.45e-05	0.000352	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ADI1—prostate cancer	3.39e-05	0.000345	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GRHL1—prostate cancer	3.39e-05	0.000345	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PSAT1—prostate cancer	3.39e-05	0.000345	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CBR1—prostate cancer	3.39e-05	0.000345	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TST—prostate cancer	3.39e-05	0.000345	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CSAD—prostate cancer	3.39e-05	0.000345	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	3.31e-05	0.000337	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	3.24e-05	0.000331	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GRHPR—prostate cancer	3.15e-05	0.000321	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UGT2B15—prostate cancer	3.15e-05	0.000321	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UGT2B17—prostate cancer	3.15e-05	0.000321	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CKMT2—prostate cancer	3.15e-05	0.000321	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	3.08e-05	0.000314	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—MED12—prostate cancer	3.03e-05	0.000309	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MBTPS1—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NAGLU—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SULT2B1—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM3—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RFK—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PGAM2—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AOX1—prostate cancer	2.96e-05	0.000302	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6—prostate cancer	2.92e-05	0.000298	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	2.89e-05	0.000295	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6—prostate cancer	2.83e-05	0.000289	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AMACR—prostate cancer	2.81e-05	0.000286	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP3A43—prostate cancer	2.81e-05	0.000286	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NAT1—prostate cancer	2.81e-05	0.000286	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SRD5A2—prostate cancer	2.81e-05	0.000286	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—DEGS1—prostate cancer	2.81e-05	0.000286	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	2.76e-05	0.000281	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—prostate cancer	2.7e-05	0.000275	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSD17B1—prostate cancer	2.68e-05	0.000273	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	2.68e-05	0.000273	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—prostate cancer	2.61e-05	0.000266	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	2.57e-05	0.000262	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	2.56e-05	0.000261	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	2.53e-05	0.000258	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	2.41e-05	0.000246	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—B4GALT4—prostate cancer	2.39e-05	0.000243	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HPGD—prostate cancer	2.39e-05	0.000243	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TNFRSF21—prostate cancer	2.24e-05	0.000229	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP7B1—prostate cancer	2.18e-05	0.000222	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTAP—prostate cancer	2.18e-05	0.000222	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2.13e-05	0.000217	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SULT1E1—prostate cancer	2.13e-05	0.000217	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SRD5A1—prostate cancer	2.13e-05	0.000217	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.07e-05	0.000211	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.03e-05	0.000207	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSD17B3—prostate cancer	2.03e-05	0.000207	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ACSL4—prostate cancer	2.03e-05	0.000207	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2e-05	0.000204	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UMPS—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PHGDH—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ARG2—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.93e-05	0.000197	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—LDHB—prostate cancer	1.91e-05	0.000194	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP3A5—prostate cancer	1.87e-05	0.000191	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PDHA1—prostate cancer	1.81e-05	0.000184	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UCP3—prostate cancer	1.81e-05	0.000184	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA3—prostate cancer	1.81e-05	0.000184	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TCN2—prostate cancer	1.81e-05	0.000184	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC22A3—prostate cancer	1.72e-05	0.000176	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSD3B1—prostate cancer	1.72e-05	0.000176	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.67e-05	0.000171	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TBXAS1—prostate cancer	1.65e-05	0.000169	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA4—prostate cancer	1.65e-05	0.000169	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.62e-05	0.000165	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA2—prostate cancer	1.61e-05	0.000164	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SULT1A1—prostate cancer	1.59e-05	0.000162	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCG5—prostate cancer	1.59e-05	0.000162	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTA1—prostate cancer	1.55e-05	0.000159	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTO1—prostate cancer	1.54e-05	0.000157	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSD3B2—prostate cancer	1.54e-05	0.000157	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NAT2—prostate cancer	1.54e-05	0.000157	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.48e-05	0.000151	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PLCB2—prostate cancer	1.47e-05	0.00015	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP2C18—prostate cancer	1.47e-05	0.00015	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—LRP2—prostate cancer	1.47e-05	0.00015	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—P4HB—prostate cancer	1.45e-05	0.000147	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC22A1—prostate cancer	1.41e-05	0.000143	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.39e-05	0.000142	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SULT2A1—prostate cancer	1.37e-05	0.00014	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MED12—prostate cancer	1.35e-05	0.000137	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GNG5—prostate cancer	1.34e-05	0.000136	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOA3—prostate cancer	1.29e-05	0.000131	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.27e-05	0.000129	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HPGDS—prostate cancer	1.23e-05	0.000125	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ACHE—prostate cancer	1.19e-05	0.000122	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTT1—prostate cancer	1.19e-05	0.000122	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP2A6—prostate cancer	1.18e-05	0.00012	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.17e-05	0.00012	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKR1C3—prostate cancer	1.15e-05	0.000117	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PRKACB—prostate cancer	1.14e-05	0.000116	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP17A1—prostate cancer	1.13e-05	0.000115	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.11e-05	0.000113	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOA2—prostate cancer	1.08e-05	0.00011	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC5A5—prostate cancer	1.03e-05	0.000105	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP2E1—prostate cancer	1e-05	0.000102	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NQO1—prostate cancer	9.9e-06	0.000101	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TH—prostate cancer	9.76e-06	9.95e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	9.7e-06	9.89e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP3A4—prostate cancer	9.66e-06	9.85e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	9.61e-06	9.8e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1B1—prostate cancer	9.5e-06	9.68e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GGT1—prostate cancer	9.2e-06	9.38e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOA1—prostate cancer	9.06e-06	9.24e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP19A1—prostate cancer	8.93e-06	9.1e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RXRA—prostate cancer	8.62e-06	8.79e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	8.38e-06	8.55e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—COMT—prostate cancer	8.3e-06	8.46e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTP1—prostate cancer	8.26e-06	8.42e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ITPR1—prostate cancer	8.13e-06	8.29e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	7.99e-06	8.15e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMS—prostate cancer	7.68e-06	7.83e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM1—prostate cancer	7.59e-06	7.74e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—LPL—prostate cancer	7.45e-06	7.6e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1A1—prostate cancer	7.2e-06	7.34e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ERCC2—prostate cancer	7.14e-06	7.28e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTHFR—prostate cancer	6.71e-06	6.84e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPARA—prostate cancer	6.58e-06	6.71e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CAV1—prostate cancer	6.19e-06	6.31e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.91e-06	6.03e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CG—prostate cancer	5.64e-06	5.75e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—INS—prostate cancer	5.34e-06	5.44e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CREBBP—prostate cancer	5.23e-06	5.33e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CD—prostate cancer	4.96e-06	5.05e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NOS3—prostate cancer	4.68e-06	4.77e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CB—prostate cancer	4.32e-06	4.4e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS2—prostate cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—prostate cancer	3.73e-06	3.81e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—EP300—prostate cancer	3.56e-06	3.63e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—prostate cancer	2.63e-06	2.69e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—prostate cancer	2.15e-06	2.19e-05	CbGpPWpGaD
